Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.32 |
| ▸ | CTSS | P25774 | 4/20 | 0.32 |
| ▸ | CTSK | P43235 | 4/20 | 0.32 |
| ▸ | CTSL | P07711 | 3/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212555 | 0.86 | LMNA (0.34) | CA1CA2ELANEP2RX7CTSS | |
| SCHEMBL14119267 | 0.84 | RNASEH1 (0.40) | CA1CA2ELANEP2RX7LMNA | |
| SCHEMBL13691700 | 0.84 | CTSS (0.36) | CTSSCTSKCTSLCTSBLMNA | |
| SCHEMBL9943017 | 0.80 | ELANE (0.33) | CA1CA2ELANEP2RX7LMNA | |
| SCHEMBL14212556 | 0.78 | MAPT (0.35) | CA1CA2ELANEP2RX7LMNA | |
| SCHEMBL14119188 | 0.77 | MAPT (0.35) | CA1CA2P2RX7LMNA | |
| SCHEMBL87310 | 0.77 | CTSK (0.33) | CTSSCTSKCTSLCTSB | |
| SCHEMBL13691511 | 0.76 | CTSK (0.34) | CTSSCTSKCTSLCTSBRNASEH1 | |
| SCHEMBL9900834 | 0.73 | LMNA (0.37) | CA1CA2ELANEP2RX7LMNA | |
| SCHEMBL9942900 | 0.70 | CTSL (0.44) | CA1CA2P2RX7CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2012078834-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CA1 4824/4885CA2 4114/4885ELANE 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.